Delivery Order SPE2DB22D9353-SPE2DB26FX1KE
- Not listed
- The Defense Logistics Agency awarded a $55,450.26 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). This delivery order, issued on October 21, 2025, with an ultimate completion date of October 22, 2025, was awarded without set-aside designation, reflecting the contractor's competitive capability in unrestricted...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $36,758.74 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order, issued on September 29, 2025, covers the supply of Trikafta 100-50-75 mg/150 mg tablets in quantities of 84 units, with a completion date of September 30, 2025. This award was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete...
- The Defense Logistics Agency awarded a $36,976.24 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The delivery order, issued on July 18, 2025, with an ultimate completion date of July 21, 2025, represents a discrete fulfillment under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA valued at...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,488.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets. The contract, which became effective on August 1, 2025, with an ultimate completion date of August 4, 2025, was issued without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger single-award...
- The Defense Logistics Agency awarded a delivery order valued at $147,904.96 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The award was issued on April 24, 2025, with an ultimate completion date of April 25, 2025, under a firm fixed-price delivery order contract type with no set-aside designation. This delivery order falls under DMS Pharmaceutical...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $36,976.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The contract, issued on August 6, 2025, with an ultimate completion date of August 7, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery...
- The Defense Logistics Agency has awarded a firm fixed-price delivery order valued at $18,488.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets. The delivery order, issued on August 13, 2025, with an ultimate completion date of August 14, 2025, represents a specialized pharmaceutical product delivery to support federal healthcare operations. This award carries no...
- The Defense Logistics Agency awarded a delivery order valued at $55,450.26 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on August 26, 2025. The delivery order, issued under contract number 4569255033, calls for the supply of Trikafta 100-50-75 mg/150 mg tablets in a quantity of 84 units. DMS Pharmaceutical Group will perform the work at its Park Ridge facility, with an ultimate completion date of August 27, 2025. The...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,488.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The award, issued on August 19, 2025, with an ultimate completion date of August 20, 2025, carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger single-award...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $205,854.67 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on September 12, 2025. The delivery order covers Trikafta 100-50-75 mg/150 mg tablets in a quantity of 84 units and is structured as a firm fixed-price contract with an ultimate completion date of September 15, 2025. This award does not utilize a set-aside designation, allowing DMS...
- SPE2DB22D9353Indefinite Delivery Contract
- SPE2DB22D9353-SPE2DB26FX1KEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $38,633.14 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg tablets in quantities of 14 packets. The delivery order, issued on October 23, 2025, with an ultimate completion date of October 24, 2025, operates under a firm fixed-price structure with no set-aside designation. This award represents a single transaction within DMS Pharmaceutical Group's broader relationship with the Defense Logistics Agency's Medical Supply Chain division, which has issued numerous delivery orders to the company for pharmaceutical products and medical consumables supporting Department of Defense healthcare operations. This delivery order is issued under DMS Pharmaceutical Group's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) indefinite delivery contract with the Defense Logistics Agency, awarded on November 13, 2025, with a ceiling value of $499,999,999 and completion date of December 31, 2036. The PPV-G GEN V represents a comprehensive $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supplying branded and generic pharmaceuticals, biologics, and medical consumables to military healthcare facilities worldwide. DMS Pharmaceutical Group's demonstrated performance across a diverse product portfolio—ranging from oncology treatments and immunosuppressants to routine medications and specialty pharmaceuticals—positions the company as a critical pharmaceutical supplier within the federal military medical supply chain.